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Abstract
Verrucarin A (VA) is a small molecule derived from the fungal plant pathogen Myrothecium verrucaria and was
identified as a selective inhibitor of clear cell renal cell carcinoma (CCRCC) cell proliferation in a high-throughput
screen of a library of naturally occurring small molecules. CCRCC arises as a result of loss-of-function mutations in
the von Hippel–Lindau (VHL) gene. Here we show that VA inhibits protein translation initiation culminating in
apoptosis through the extrinsic signaling pathway. Reintroduction of the VHL gene in CCRCC cells afforded resis-
tance to VA’s apoptotic effects. This resistance is mediated in part by the formation of stress granules that entrap
signaling molecules that initiate the apoptotic signaling cascade. The VHL gene product was found to be a com-
ponent of stress granules that develop as result of VA treatment. These findings reveal an important role for
the VHL gene product in cytotoxic stress response and have important implications for the rational development
of VA-related compounds in chemotherapeutic targeting of CCRCC.
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Introduction
A lack of clear early warning signs, a wide range of symptoms and
resistance to radiation and chemotherapy all characterize von Hippel–
Lindau (VHL)–associated clear cell renal cell carcinoma (CCRCC).
Underlying the disease are loss-of-functionmutations in theVHL tumor
suppressor gene [1]. Currently, several drug discovery approaches are
being explored for targeting the disease, and recently, we reported on
the use of a high-throughput screen (HTS) that identified several natural
molecules that showed selective cytotoxicity to VHL-defective (VHL−/−)
CCRCC cells [2]. Verrucarin A (VA) was one of the compounds iden-
tified in this HTS campaign. The compound, also known as mucono-
mycin A, had previously been described as a protein synthesis inhibitor
[3]. However, several protein synthesis inhibitors that were part of the
screening library did not demonstrate differential cytotoxicity between
paired VHL−/− and VHL-competent (VHL+/+) CCRCC cells. We,
therefore, undertook this study to better characterize the mechanism
behind the toxicity of VA in CCRCC cells and to examine the role
played by the VHL gene product (pVHL) in mediating response to
cytotoxic stress induced by VA.
Abbreviations: cFLIP, cellular–FLICE inhibitory protein; CHX, cycloheximide;
CCRCC, clear cell renal cell carcinoma; HTS, high-throughput screen; pVHL,
VHL gene protein product; SG, stress granule; VA, verrucarin A or muconomycin A;
VHL, von Hippel–Lindau; VHL−/−, VHL-defective; VHL+/+, VHL-competent
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Materials and Methods
Reagents
VA, purchased from Sigma, St Louis, MO (catalog no. V4877), was
dissolved in dimethyl sulfoxide (DMSO) and stored as 20-mM aliquots
at −20°C. Cycloheximide (CHX; catalog no. C4859), verrucarol (cat-
alog no. V1628), and heparin (catalog no. H4784) were also obtained
from Sigma. Ultrapure sucrose (catalog no. 15503) and Tris-HCl
(catalog no. 15567) were purchased from Invitrogen (Grand Island,
NY). Didemnin B and 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-
2H -tetrazolium-5-carboxanilide were obtained from theDrug Synthesis
and Chemistry Branch (National Cancer Institute, Bethesda, MD).
Cells and Cell Culture
786-O, UOK-121, RCC4, and UOK-127 cell lines, character-
ization, and growth and propagation conditions have been described
previously [2]. Throughout their use, cell morphology, growth curve,
and possible mycoplasma contamination were regularly monitored.
786-ONLS-VHL and 786-ONES-VHL cells were generated through
transient transfection of 786-O cells with the previously described
NLS-VHL-ef-IRES-puro and NES-VHL-ef-IRES-Puro constructs,
respectively [4].
Western Blot Analysis
Cell lysates for Western blot analysis were prepared as described
earlier [2]. Briefly, 30 μg of protein from lysates was separated by
SDS-PAGE, transferred to polyvinylidene difluoride membranes,
blocked overnight in Odyssey blocking buffer (Li-Cor, Lincoln,
NE) at 4°C, and incubated with primary antibodies obtained from
Cell Signaling, Danvers, MA (cleaved caspase 3, cleaved caspase 8,
eIF2α, p-eIF2α, p38, p-p38, PARP, S6, p-S6, survivin, VHL) and
Santa Cruz Biotechnology, Santa Cruz, CA (cFLIPS/L, JNK, pJNK).
After incubating with primary antibodies, membranes were washed
and incubated with anti-mouse IRDye 680 and anti-rabbit IRDye
800 secondary antibodies (Li-Cor). Blots were scanned using an
Odyssey infrared imaging system, and band intensities were deter-
mined using the Odyssey band quantitation software after background
subtraction using the median top-bottom method. Intensities of bands
of interest were normalized to the signals from the corresponding
loading control bands of β-actin, α-tubulin, or GAPDH. In addition,
Ponceau S staining of membranes was also used as loading control.
Flow Cytometry Analysis
After treatment with 10 nM VA for 4 hours, cells were harvested
using Accutase (catalog no. A11105; Invitrogen) and stained with
Annexin V–propidium iodide (PI) (catalog no. V13245; Invitrogen),
anti-CD262 (catalog no. 12-9908)-7AAD (catalog no. 559925; BD
Pharmingen, Franklin Lakes, NJ), anti-CD95 (catalog no. 12-0959;
eBioscience, SanDiego, CA)-7AAD, anti-CD178 (catalog no. 12-9919)-
7AAD, or mouse IgG1 K Isotype control (catalog no. 12-4714)-7AAD.
Data were acquired on an Accuri C6 flow cytometer (BD) and exported
into FCS express 4 software for analysis.
Ribosome Isolation and Polysome Profile Analysis
For ribosome isolation, untreated cells and cells treated for 10 min-
utes at 37°C with the cross-linker bis-maleimidohexane (90 μM in
phosphate-buffered saline [PBS]; Molecular Biosciences, Boulder,
CO) were lysed after pelleting by resuspending in low-salt ribosome
extraction buffer (20 mM Tris-HCl pH 7.5, 50 mM KCl, 10 mM
MgCl2, 1 mM dithiothreitol, Halt protease inhibitor cocktail, 100 μg/ml
CHX, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 200 μg/ml heparin in diethylpyrocarbonate (DEPC)-treated
water). Highs-salt ribosome extraction buffer contained 500 mM KCl
instead. After incubating on ice for 10 minutes, the lysate was centri-
fuged at 10,000g for 10 minutes at 4°C and the supernatant (cytosolic
extract) was used. This cytosolic extract was centrifuged at 100,000g
for 2 hours on a 15% sucrose cushion for isolation of ribosomes and
ribosomal subunits. The pellet, which included polysomes, monosomes,
and ribosomal subunits, was suspended in a NuPAGE (Invitrogen)
sample loading buffer, whereas the supernatant was also resuspended
in the same loading buffer after precipitation of proteins with 10%
trichloroacetic acid.
For polysome profile analysis, equal numbers of cells seeded into
two T-225 flasks and incubated overnight were used (70%-80%
confluent). Cells in one flask were treated with 5 μg/ml VA, whereas
cells in the second flask received DMSO treatment. Both flasks were
incubated for 15 minutes at 37°C and treated with CHX at a final
concentration of 100 μg/ml for 15 minutes. After incubating at 37°C,
cells were trypsinized in PBS containing CHX. Trypsinized cells
were rinsed with ice-cold PBS + CHX and lysed with 400 μl of ribo-
some extraction buffer. Lysates were then cleared by centrifugation at
10,000g for 10 minutes, and cleared supernatants were loaded onto
sucrose gradients. These gradients were prepared by layering 2 ml
each of 47%, 37%, 27%, 17%, and 7% sucrose in ribosome extrac-
tion buffer (without heparin and Triton X-100) and allowed to stand
at 4°C for 16 hours. Loaded gradients were then subjected to ultra-
centrifugation (Beckman L8-80M, 39,000 rpm, SW41Ti rotor;
Beckman, Palo Alto, CA) for 165 minutes. While monitoring absorbance
at 254 nm, fractions were collected from the top through displacement
by injecting 60% sucrose at the bottom of the gradient at 1.0 ml/min
(ISCO 640 density gradient fractionator; ISCO, Lincoln, NE).
Immunocytochemistry
Cells pretreated with either DMSO or VA for 24 hours were har-
vested and allowed to attach to glass chips with Y-shaped fibronectin
micropatterns (catalog no. 11-012-10-12; CYTOO, Grenoble, France).
After allowing them to spread, cells were fixed with 4% fresh para-
formaldehyde and permeabilized with 0.1% Triton X-100 in PBS.
Samples were blocked using Odyssey blocking buffer overnight at 4°C.
Anti–TIA-1 (1:100, catalog no. sc-1751; Santa Cruz Biotechnology) or
anti-VHL (1:100, catalog no. 2738; Cell Signaling) antibodies were
incubated with samples overnight at 4°C. Finally, samples were washed
and incubated for 45 minutes with Alexa Fluor 488 goat anti-rabbit
(catalog no. A31628; Invitrogen) and Alexa Fluor 594 goat anti-mouse
(catalog no. A31624; Invitrogen). Counterstaining was done using
ProLong Gold antifade reagent with DAPI (catalog no. P36931;
Invitrogen) as the mounting medium. Images were acquired using Zeiss
LSM 510 microscopes at 63× magnification (Zeiss, Thornwood, NY).
Colocalization studies were performed as described previously using
ImageJ software [2].
Statistical Analysis
Student’s t test was performed to determine the statistical signifi-
cance of differences between treated and control groups. P < .05 was
calculated in all experiments where applicable and was considered
statistically significant. Error bars represent SEM of three indepen-
dent experiments run in parallel in triplicate in all plots.
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Results
VA Inhibits CCRCC Cell Proliferation and Induces Apoptosis
While screening for inhibitors of VHL-defective cell proliferation
[2], VA, a trichothecene isolated from yeast, was found to selectively
inhibit the proliferation of pVHL-defective (VHL−/−) CCRCC cells
786-O, RCC4, UOK-121 and UOK-127 with half-maximal inhib-
itory concentrations (IC50) between 10 and 100 nM. VA was also
found to significantly impact clonogenicity of CCRCC cells
(Figure 1A). Its IC50 value in pVHL-competent (VHL
+/+) 786-
OVHL, RCC4VHL, UOK-121VHL, and UOK-127VHL cells
was found to be between 10 and 100 μM. We then proceeded to
determine whether this level of activity was specific to CCRCC cells
by testing VA against a panel of VHL+/+ non-CCRCC renal cancer
cell lines. Evaluation of its impact on cell proliferation in these cell
lines also gave IC50 values between 3 and 30 μM, confirming that it
possessed a selective effect in VHL−/− CCRCC cells (Table W1).
Direct observation of VA-treated CCRCC cells under a micro-
scope revealed cell shrinkage and membrane blebbing, suggesting
apoptotic cell death. Analysis of Annexin V and PI double-stained
786-O and 786-OVHL cells by flow cytometry after treatment with
VA confirmed this observation (Figure 1B). To better characterize
the mechanism by which VA curtailed CCRCC cell proliferation,
its effect on multiple apoptosis pathway components was examined.
No appreciable changes in the level of the Bcl-2 family of proteins
were seen on VA treatment (data not shown), suggesting that
apoptosis may be initiated through the extrinsic signaling pathway.
Therefore, we next looked at cell surface changes of death receptor
Figure 1. Inhibition of proliferation of CCRCC cells by VA and induction of apoptosis. (A) Clonogenic survival assay of VA-treated 786-O cells.
786-O cells were treated with increasing concentrations of VA for 24 hours. After harvesting, cells were seeded at 100 cells/dish in 60-mm
dishes in completemedium and allowed to grow for 14 days. Colonieswere fixed and stainedwith crystal violet. (B) Flow cytometric analysis
of PI and Annexin V double-stained 786-O and 786-OVHL cells. Cells were treated for 24 hours with 10 nMVA or DMSO. Percentages of cells
in each quadrant shown are from one representative experiment. (C) 786-O cells were analyzed by flow cytometry for cell surface expression
of DR5. Cells were stained with phycoerythrin (PE)-conjugated isotype control (black) or DR5-PE after control (gray) or VA (unshaded, 10 nM)
treatment. (D) CCRCC cells were treated with control, VA (10 nM), TRAIL (20 ng/ml), or VA + TRAIL for 24 hours. Cell viability was assessed
using 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H -tetrazolium-5-carboxanilide reduction. (E) Time course ofWestern blot analysis of apopto-
sis signaling proteins in 786-O cells treated with 10 nM VA. A representative β-actin blot is shown as a loading control.
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pathway components including Fas (CD95), Fas ligand (CD178),
and TRAIL death receptors 1 (DR4) and 2 (DR5). Using flow
cytometry analysis, we detected a significant increase only in the cell
surface expression levels of DR5 (Figure 1C ).
CCRCC cells are known to be TRAIL resistant [5]. As a result, we
sought further confirmation for increased cell surface expression of
DR5 by carrying out a TRAIL sensitization experiment. It was found
that pretreatment of CCRCC cells with VA increased their sensitivity
to TRAIL (Figure 1D). Also, because resistance to TRAIL-induced
apoptosis in CCRCC has been linked to the high level of expression
of the antiapoptotic molecule survivin [6], we examined whether VA
treatment affected the expression level of this protein. Western blot
analysis data revealed that VA treatment downregulated survivin levels
in CCRCC cells (Figure 1E ). Overexpression of survivin in CCRCC
cells, on the other hand, increased their resistance to VA (Figure W1).
Because the cellular-FLICE inhibitory protein (cFLIP) acts as an
immediate inhibitor of death receptor–mediated proapoptotic signal-
ing, we also looked at changes in its level in response to VA treat-
ment. VA was found to decrease the levels of both the long and
short splice variants of cFLIP (Figure 1E ). Probing changes in the
levels of other components of the death-inducing signaling complex
through Western blot analysis revealed that, although VA treatment
did not affect caspase 9 levels, it induced caspase 8 cleavage (Figure 1E ).
Thus, based on the above findings, it seems that VA treatment triggers
death receptor–induced cell death through changes in the level of com-
ponents of the death-inducing signaling complex in CCRCC cells.
VA Inhibits Translation in CCRCC Cells
Previous studies carried out with VA in yeast have shown that it
inhibits protein synthesis in vitro [7]. Therefore, we asked whether its
proapoptotic effects in CCRCC cells were related to its effect on pro-
tein synthesis. First, its impact on overall protein levels in cells was
assessed using a fluorescent-labeling experiment for incorporation of
L-azidohomoalanine, a methionine analog, in nascent protein synthesis.
This showed that VA caused a decrease in total protein levels in cells
in a dose dependent manner. Interestingly, it caused a smaller decrease
in total protein levels in VHL+/+ cells compared to VHL−/− cells at all
concentrations tested (Figure W2A).
To determine whether the differential impact on proliferation
between VHL−/− and VHL+/+ CCRCC cells was specific to VHL−/−
CCRCC cells or whether it is a property shared by protein synthesis
inhibitors in general, we also tested inhibitors of translation initiation
(hippuristanol, verrucarol) and translational elongation (anisomycin,
puromycin, didemnin B, and CHX). Although anisomycin and didem-
nin B showed selectivity toward inhibition of cell proliferation inVHL−/−
cells, their activity was significantly weaker than that observed with VA,
suggesting that VA had a specific and selective activity in VHL−/−
CCRCC cells (Figure W2B).
We also examined the specific effects of VA on the protein synthesis
machinery using ultracentrifugation and sedimentation of ribosomal
extracts over a sucrose gradient. Compared with DMSO-treated con-
trol cells, VA-treated 786-O cells displayed elevated 80S peaks with sig-
nificant reduction in polysomal peaks (Figure 2A). Although VA also
caused an increase in 80S peaks in 786-OVHL cells, this increase was
not as dramatic as its effect in 786-O cells. It also had a less pronounced
effect on polysomes in 786-OVHL cells. Further evidence on its effect
on the ribosome came from Western blot analysis data (Figure 2B),
showing induction of phospho-ribosomal protein S6, phospho-eIF2α,
phospho-p38, and phospho-JNK [8]. However, pretreatment with
JNK or p38 inhibitors did not reverse or attenuate apoptotic effects
of VA, suggesting that, although it induces cellular stress, signaling
through p38 or SAPK/JNK was not required for its effects.
pVHL Binds the Ribosome
pVHL is known to shuttle between the cytosol and the nucleus in
cells [9]. Therefore, we next asked whether its nuclear or cytosolic
effects were responsible for resistance to VA. To answer this question,
786-ONLS-VHL and 786-ONES-VHL cells were generated through
transfection with VHL constructs where the VHL gene was tagged with
either a nuclear localization signal (NLS-VHL) or a nuclear export sig-
nal (NES-VHL), respectively. Evaluation of VA in these cell lines
showed that, compared with 786-O empty vector–transfected cells,
Figure 2. Effect of VA on protein synthesis and stress induction. (A) Representative sucrose density gradient sedimentation polysome
profiles of ribosomes extracted from control and VA-treated 786-O and 786-OVHL cells. (B) Time course of Western blot analysis of
stress signaling pathway proteins in 786-O cells treated with 10 nM VA. A representative β-actin blot is shown as a loading control.
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both cells lines were more resistant to VA, suggesting that both nuclear
and cytosolic effects of pVHL play a role in resistance. Interestingly,
however, 786-ONES-VHL cells seemed more resistant to VA than
786-ONLS-VHL cells (Figure 3A).
As a result, we asked whether resistance to VA in VHL+/+ cells was
due, in part, to pVHL’s direct role on the protein synthesis machinery.
First, we examined whether pVHL binds the ribosome and found that
it sedimented along with proteins of the ribosomal fraction of CCRCC
cells prepared with a low-salt-containing ribosomal extraction buffer
that maintains total ribosomal integrity (Figure 3B). In contrast, when
ribosomal integrity was disrupted with high-salt-containing ribosomal
extraction buffer, pVHL was absent from the protein pellet. Pretreat-
ment of cellular proteins with a protein cross-linking reagent before
extraction of ribosomes with a high-salt-containing buffer, on the other
hand, led to the detection of pVHL in the protein pellet from ribo-
somes fractionated over a sucrose cushion. Taken together, the above
data suggest that pVHL binds the ribosome.
VA Induces Stress Granule Formation in
VHL+/+ CCRCC Cells
VHL+/+ cells were monitored under a microscope for any changes
in their appearance upon VA treatment. The images obtained
showed the appearance of punctate cytosolic structures, absent in
VA-treated VHL−/− cells, reminiscent of stress granules (SGs) as early
as 30 minutes after treatment with 1 μM VA. In Western blots, we
found indirect evidence that VA causes SG formation in VHL+/+ cells
where up-regulation of phosphorylated eIF2α (Figure 4A), often a
trigger for stress-induced formation of SG [10], was observed.
We also sought support for SG formation through immuno-
fluorescence using TIA-1 as a marker for SGs. VA-treated VHL+/+
cells probed with an antibody to TIA-1 showed the expected positive
staining in these structures. Next, because SGs are absent in VA-treated
786-O cells and because pVHL was found to bind ribosomes, we asked
whether pVHL was a component of SGs in VA-treated VHL+/+ cells.
We carried out immunofluorescence colocalization experiments on
VA-treated cells attached to Y-shaped fibronectin micropatterns on
glass chips. This allowed for better quantification through normaliza-
tion of cell shape and internal cell organization. The results showed
that, in 786-OVHL cells stained with both anti-pVHL and anti-
TIA-1 antibodies, 73% ± 8.2% (median ± median absolute deviation)
of SG compartments showed VHL signals while 19% ± 7.3% of total
VHL signals overlapped the TIA-1 staining (Figure 4B). These find-
ings suggest that VA treatment induces SG formation in VHL+/+
CCRCC cells and that pVHL is a component of, and might play a role
in, SG formation.
Discussion
The number of cases where CCRCC continues to be refractory to
conventional treatments still remains high. As a result, there is an
urgent need to identify new chemotherapeutic agents. Selective inhib-
itors of VHL-defective cell proliferation thus represent an attractive
class of compounds as they exploit vulnerabilities introduced in
CCRCC cells as a result of the loss of functional pVHL. Furthermore,
such compounds will not only serve as tools to better characterize the
pathobiology behind CCRCC but can also be potential starting
points for the development of small molecule-based therapeutic
agents. We recently reported carrying out an HTS campaign to iden-
tify such natural small molecules [2]. One of the hit compounds to
show potent and selective inhibition was VA, a compound derived
from the yeast M. verrucaria. Through work primarily done in yeast,
the compound has been shown to be an inhibitor of protein synthesis
and has been used as such in many studies with mammalian cells [7].
Despite the range of cell lines where this effect has been documented,
the compound shows selectivity in inhibiting the proliferation of
renal carcinoma cells, which lack a functional product of the VHL
gene. In this study, we provide some novel insights into selective
death receptor–mediated apoptosis in CCRCC cells and the role of
pVHL in mediating response to cytotoxic stress by an inhibitor of
protein translation initiation—VA.
We found that VA induces selective inhibition of the proliferation
of pVHL-defective CCRCC cells, whereas reintroduction of pVHL
engenders resistance to VA in CCRCC cells. Our preliminary results
with VA inVHL−/− cells for hypoxia-inducible factor 2–driven luciferase
expression, in chetomin-pretreated VHL−/− cells and in pretreatment
with a hypoxia mimic in VHL+/+ cells, revealed that VA’s effect was
not hypoxia-inducible factor related, the most well-characterized target
of pVHL activity. However, we found that the compound caused apop-
totic and not necrotic or autophagic cell death. Lack of any significant
alterations in the levels of Bcl-2, Bax, Bad, Bak, Bid, and Bim or of
any detectable cytochrome c release into the cytosol indicated that apop-
tosis in CCRCC cells was mitochondria independent. Data from flow
Figure 3. pVHL’s cytosolic role in VA-treated 786-OVHL cells. (A)
The effects of nuclear and cytosolic pVHL on resistance to VA’s
effects on cell proliferation. (B) Western blot analysis of protein
components in pellets (P) and supernatant (S) obtained by centri-
fugation of ribosomes extracted with low- (L) and high- (H) salt
buffers from control- (−) and VA- (+) treated cells. The protein
cross-linking reagent bis-maleimidohexane (BMH) was used to
confirm pVHL binding of ribosomes extracted with high salt.
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cytometry and Western blot analysis of components of the extrinsic
apoptosis signaling pathway proteins confirmed the up-regulation of
the TRAIL death receptor DR5 on the cell surface and the down-
regulation of cFLIP. Previous reports show that cFLIP down-regulation
can induce ligand-independent but DR5-, FADD-, and caspase-
dependent apoptosis [11]. Our findings are consistent with this obser-
vation because no appreciable changes in FADD levels were detected in
VA-treated cells while the CCRCC cells tested, notorious for being
resistant to TRAIL-mediated apoptosis [12], became more sensitive to
the effects of TRAIL on pretreatment with VA.
Also consistent with previous findings that showed VA inhibits
protein synthesis, we found that the compound inhibited translation
at or immediately after initiation in CCRCC cells as evidenced by a
dramatic increase in monomeric 80S ribosomal content and a decrease
in polysomal content. This seems to suggest that VA has a dramatic
impact on cap-dependent translation initiation. However, evaluation
of classical markers of ribosomal and ER stress such as degradation of
18S or 28S rRNA, up-regulation of GRP78, CHOP/GADD153 or
HSP70, and Ca2+ release into the cytosol from the ER lumen were
all absent in treated CCRCC cells. On the other hand, we found that
VA induced up-regulation of phospho-eIF2α, a marker for “ribotoxic
stress” response during treatment with the trichothecene family of com-
pounds, of which VA is a member [13]. Further studies will be needed
to elucidate the mechanism linking this nonclassic ribotoxic stress to
apoptosis signaling through the extrinsic pathway.
In VA-treatedVHL+/+CCRCC cells, the ribosomal profile obtained
after ultracentrifugation over sucrose gradients of ribosomal extracts
revealed a slight increase in 80S ribosomal content. This suggests
that cap-dependent translation initiation may also be impacted as
with VHL−/− cells, albeit to a lesser extent. On the other hand, VA
seemed to have little impact on polysomal content in these cells,
indicating that it does not significantly affect either polysomal or cap-
independent translation.
When examining any potential direct roles of pVHL on compo-
nents of the translational machinery, we found that pVHL binds ribo-
somes. Investigations into whether its nuclear or cytosolic functions
contributed to resistance to VA showed that both its nuclear and cyto-
solic activities contributed to resistance with cytosolic pVHL, engen-
dering an increased resistance compared to nuclear pVHL. Findings
from immunofluorescence and colocalization studies suggested that
VA induced SG formation and that, in the cytosol, pVHL was found
in SGs in VHL+/+ cells. SGs represent an aggregation of stalled trans-
lation initiation complexes [14] and various components of stress gran-
ules, including phospho-eIF2α, are known to mediate apoptotic
signaling. Studies have shown that sequestration of these signaling
molecules in SGs can lead to abrogation of stress-induced apoptosis
signaling [15]. Furthermore, it has been shown that the limiting step
in messenger RNA translation is the competition for limiting amounts
of translation initiation factors [16]. With depletion of translation ini-
tiation complexes through SG formation, pVHL’s role in stabilizing a
Figure 4. Induction of stress by VA in 786-OVHL cells leads to stress granule formation. (A) Western blot analysis of time course lysates
from VA-treated 786-OVHL cells probed with anti-eIF2α and anti–p-eIF2α antibodies. (B) Subcellular localization of pVHL (green) and the
stress granule marker TIA-1 (red) in 786-OVHL cells. Cells were treated with either VA or DMSO control before staining. Images shown
are from a representative cell obtained after allowing cells to adhere to Y-shaped fibronectin micropatterns that allow normalization of
cell shape, position, polarity, and internal organelle positioning. Colocalization analysis was undertaken as described in the Materials and
Methods section.
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number of prosurvival messenger RNAs that are otherwise “weak”
competitors for available translation initiation factors may be significant
in preventing apoptosis [17].
Taken together, our results suggest that selective targeting of VHL−/−
cells might be possible in CCRCC through the use of specific inhibitors
of translation initiation. It seems that VHL+/+ cells are better able to
handle the stress induced by such compounds. The evidence provided
in this study suggests the presence of vulnerability in CCRCC cells that
may be exploited for therapeutics development.
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Table W1. The IC50 Value of VA Was Determined in a Panel of CCRCC and Non-CCRCC
Cell Lines.
Cell Line IC50 (VHL
−/−) (nM) IC50 (VHL
+/+) (μM)
786-O 3.32 1.42
UOK-121 30.10 37.34
UOK-127 50.20 29.52
RCC4 12.54 33.44
UO-31* 9.82
A498 43.74
SN12C* 23.65
ACHN* 23.30
A498VHL cell line was not generated, and therefore, its IC50 value was not determined.
*Non-CCRCC cell lines.
Figure W1. Overexpression of survivin in the CCRCC cell line 786-O
increased resistance to apoptosis by VA. 786-O cellswere transiently
transfectedwith the expression vector pcDNA3-HA-Survivin (catalog
no. 131002; CH3 BioSystems, Amherst, NY) to generate 786-OSurvivin
cells. As a control, 786-O cells were transfected with the empty
pcDNA3-HA vector (shown in the graph as 786-O).
Figure W2. Differential effect of small-molecule protein synthesis inhibitors on protein synthesis and proliferation in 786-O and 786-
OVHL cells. (A) VA shows a differential effect on protein synthesis between 786-O and 786-OVHL cells. Cells being grown in 12-well
plates were incubated in fresh methionine-free growth medium for 30 minutes. The medium was replaced with either control or VA
containing methionine-free medium supplemented with 50 μM L-azidohomoalanine, and cells were further incubated for 30 minutes.
After washing, cells were then labeled in the dark with DIBO–Alexa Fluor-488 at room temperature for 1 hour. Finally, fluorescence from
wells was measured in PBS. (B) Of the different protein synthesis inhibitors tested, only didemnin B and aninomycin showed differential
growth inhibitory effect between 786-O and 786-OVHL cells.
